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Abstract
Sulfated polysaccharides from Laminaria saccharina (new name: Saccharina latissima) brown seaweed show promising
activity for the treatment of inflammation, thrombosis, and cancer; yet the molecular mechanisms underlying these
properties remain poorly understood. The aim of this work was to characterize, using in vitro and in vivo strategies, the anti-
inflammatory, anti-coagulant, anti-angiogenic, and anti-tumor activities of two main sulfated polysaccharide fractions
obtained from L. saccharina: a) L.s.-1.0 fraction mainly consisting of O-sulfated mannoglucuronofucans and b) L.s.-1.25
fraction mainly composed of sulfated fucans. Both fractions inhibited leukocyte recruitment in a model of inflammation in
rats, although L.s.-1.25 appeared to be more active than L.s.-1.0. Also, these fractions inhibited neutrophil adhesion to
platelets under flow. Only fraction L.s.-1.25, but not L.s.-1.0, displayed anticoagulant activity as measured by the activated
partial thromboplastin time. Investigation of these fractions in angiogenesis settings revealed that only L.s.-1.25 strongly
inhibited fetal bovine serum (FBS) induced in vitro tubulogenesis. This effect correlated with a reduction in plasminogen
activator inhibitor-1 (PAI-1) levels in L.s.-1.25-treated endothelial cells. Furthermore, only parent sulfated polysaccharides
from L. saccharina (L.s.-P) and its fraction L.s.-1.25 were powerful inhibitors of basic fibroblast growth factor (bFGF) induced
pathways. Consistently, the L.s.-1.25 fraction as well as L.s.-P successfully interfered with fibroblast binding to human bFGF.
The incorporation of L.s.-P or L.s.-1.25, but not L.s.-1.0 into Matrigel plugs containing melanoma cells induced a significant
reduction in hemoglobin content as well in the frequency of tumor-associated blood vessels. Moreover, i.p. administrations
of L.s.-1.25, as well as L.s.-P, but not L.s.-1.0, resulted in a significant reduction of tumor growth when inoculated into
syngeneic mice. Finally, L.s.-1.25 markedly inhibited breast cancer cell adhesion to human platelet-coated surfaces. Thus,
sulfated fucans are mainly responsible for the anti-inflammatory, anticoagulant, antiangiogenic, and antitumor activities of
sulfated polysaccharides from L. saccharina brown seaweed.
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Introduction
Fucoidans represent an intriguing class of fucose-enriched sulfated
polysaccharides found in the extracellular matrix of brown algae.
These polysaccharides have been tested in a vast array of
experimental models showing anti-coagulant, anti-tumor, immuno-
modulatory, anti-inflammatory, and anti-complement properties [1–
6]. Detailed chemical structures of fucoidans depend primarily on the
algal species used as source of polysaccharides [3,6,7]. However, even
a sulfated polysaccharide isolated from a given species of brown algae
may be a mixture of structurally different polymers. Thus, in spite of
increasing efforts, the structure-activity relationship (SAR) of
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fucoidans is still an unresolved issue. Recently we have investigated
the anti-inflammatory, anti-coagulant, anti-angiogenic, and anti-
adhesive activities of nine different fucoidans isolated from Laminaria
saccharina (renamed as Saccharina latissima [8]) L. digitata, Cladosiphon
okamuranus, Fucus evanescens, F. vesiculosus, F. serratus, F. distichus, F.
spiralis, and Ascophyllum nodosum as pool samples [2,9]. We found that
the different profiles of biological activities exhibited by these
polysaccharides depend on variations of their structural features.
Interestingly, among the most active compounds studied, those
extracted from L. saccharina have been characterized by their
prominent anti-angiogenic and anti-coagulant activities in vitro as
well as their ability to block selectin-mediated inflammation in vivo.
Here we investigated the biological profiles of two main
components of the parent sulfated polysaccharide extracted from L.
saccharina (L.s.-P). Serial fractionation by ion-exchange chroma-
tography produced two main fractions differing in the monosaccha-
ride composition and sulfate content [10]. The first fraction eluted
from DEAE-Sephacel by 1.0 M NaCl (L.s.-1.0) consisted mainly of
sulfated fucomannoglucuronan (Figure 1A) and not of fucoidan-
related polysaccharides. The second fraction eluted by 1.25 M NaCl
(L.s.-1.25) consisted mainly of sulfated fucans (Figure 1B), which
structurally corresponds to the previously reported fucoidan from L.
saccharina [11]. The presence of fucomannoglucuronan component
in L.s.-P was surprising as this component was not clearly visible in
the NMR spectra of L.s.-P [11]. To determine how L.s.-1.0 and
L.s.-1.25 account for the biology activities of L.s.-P, we performed
comparative studies of these purified fractions in terms of anti-
inflammatory, anti-coagulant, anti-angiogenic, anti-tumor, and anti-
adhesive functions. Results presented here provide for the first time,
experimental evidence in vitro and in vivo showing that it is possible
to dissect out the chemical structures responsible for the anti-
inflammatory, anti-angiogenic, and anti-tumor activities of sulfated
polysaccharides from L. saccharina.
Materials and Methods
Isolation and purification of sulfated polysaccharides
from L. saccharina
The procedure for isolation of L.s.-P from L. saccharina has
been described earlier [11]. Separation of L.s.-P into fractions
L.s.-1.0 and L.s.-1.25 was performed by ion-exchange chroma-
tography. Structural characterization of obtained fractions was
conducted as previously reported [10]. The structures of the main
polysaccharide components of fractions L.s.-1.0 and L.s.-1.25
are shown in Figure1. The sulfate contents of the starting
polysaccharide preparation L.s.-P and its fractions are presented
in Table 1. Potential traces of endotoxin contamination were
carefully removed from fucoidan fractions by the Detoxi-GelTM
endotoxin removing gel (Pierce) and tested as described [12] using
a Gel Clot Limulus Test raising levels lower than 0.5 IU/mg;
Cape Code).
Clotting time assay
Anti-coagulant activity of polysaccharide samples was measured by
means of an activated partial thromboplastin time (APTT) clotting
assay according to the methods described [13]. Briefly, 80 ml of
pooled human plasma from healthy donors were mixed with 20 ml of
a solution containing 0–5 mg of sulfated polysaccharides in 0.9%
NaCl, and the mixture was incubated for 1 min at 37uC. Then,
100 ml of a reagent containing a mixture of phospholipids and an
activator were added, and the resulting mixture was incubated for
2 min at 37uC. Finally, a solution of 0.025 M CaCl2 (100 ml) was
added to the mixture at 37uC. The time of clot formation was
measured. The activity of L.s.-P or its fractions was expressed as
heparin units/mg, using a parallel curve obtained with heparin
standard (Fluka) with an activity of 140 U/mg.
Cell cultures
All performed cell culture experiments were approved by local
Institutional Review Board of the University of Chieti (Italy). With
the written consent of the parents, fresh human umbilical cords
were obtained from full-term births, aseptically stored in sterile
saline and processed within 6 hours from partum to obtain
endothelial cells. Human umbilical vein endothelial cells (HU-
VECs) were isolated by collagenase digestion as previously
described [14]. HUVECs from passage 1 to 5 were grown on
gelatin-coated dishes in 199 Medium (M199) containing 10% FBS
(Gibco), supplemented with 12 U/ml heparin and 50 mg/ml
bovine crude endothelial cell growth factor (ECGF) at 37uC under
5% CO2. MDA-MB-231 breast cancer cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum. Fibroblasts were grown
in DMEM supplemented with 10% fetal calf serum (FCS) (Gibco).
B16-F10 mouse melanoma cells were cultured in DMEM
essentially as described [12].
Isolation of platelets and polymorphonuclear neutrophils
(PMNs) from human blood
Blood was collected from healthy volunteers who had not
received any medication for at least 2 weeks. They were selected
among staff scientists of the Institute Consorzio Mario Negri Sud
and donated their blood for research purposes. Written consent of
donors and the approval from the institutional (Consorzio Mario
Negri Sud) Review Board were obtained for these studies. All
further in vitro assays are performed in University of Chieti following
the guidelines of Institutional Ethics Committee, University of
Chieti. Blood was anti-coagulated with 3.8% trisodium citrate at a
9:1 ratio. Human platelets were prepared by differential centrifu-
gation as described [2]. After removing the platelet-rich plasma,
PMNs were isolated by dextran sedimentation followed by Ficoll–
Hypaque gradient and hypotonic lysis of erythrocytes. PMNs were
washed and resuspended in HEPES–Tyrode’s buffer (pH 7.4)
containing 129 mM NaCl, 9.9 mM NaHCO3, 2.8 mM KCl,
Figure 1. Putative structures of the main components of the
fractions L.s.-1.0 (A) and L.s.-1.25 (B) obtained from the total
sulfated polysaccharide preparation L.s.-P extracted from L.
saccharina.
doi:10.1371/journal.pone.0017283.g001
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0.8 mM KH2PO4, 0.8 mM MgCl2.6H2O, 5.6 mM glucose,
10 mM HEPES and 1 mM CaCl2.
Platelet monolayers
Glass cover slips were coated with 4% 3-aminopropyltriethox-
ysilane (APES) in acetone. 500 ml of 1 M CaCl2 containing 3.5610
7
platelets/ml were stratified on APES-coated glass-slides, and platelets
were allowed to adhere for 3 h at room temperature. The density and
confluence of platelet layers were examined by light microscopy.
Flow adhesion assay
PMNs adhesion to adherent platelets was investigated in a
parallel plate flow chamber under physiologic flow. Platelet-coated
slides mounted in a flow chamber were placed in a thermoregulated
plexiglass box maintained at 37uC by an electric heating element.
The platelet surface was perfused with 5 ml of a PMN suspension
(106/ml in 0.1% bovine serum albumin (BSA)/DMEM) at a wall
shear stress of 2 dynes/cm2 for 2 min followed by perfusion with a
cell-free medium at a wall shear stress of 10 dyne/cm2 for 2 min in
order to remove nonadherent PMNs. The interaction of PMNs with
platelets was observed by phase contrast video microscopy with a
20X/NA objective (Olympus, Munich, Germany), and the images
were continuously recorded for playback analysis (Pro-Series video
camera, High Performance CCD camera, Media Cybernetics,
Silver Spring, MD). Adherent PMNs were counted at the end of the
perfusion in four randomized fields by using an ad hoc software for
image analysis (Image Pro-Plus for Windows, Media Cybernetics,
Silver Spring, MD) and reported as percentage6 SD, compared to
control. In selected experiments, P-selectin or the b2-integrin
adhesive function was blocked by incubating platelets or PMNs for
10 min at RT with 20 mg/ml of monoclonal antibodies, WAPS 12.2
and IB4 [15], respectively. The platelets were pre-incubated with
L.s.-P or its fractions (100 mg/ml, 500 ml/slide) for 15 min at RT
before PMNs perfusion.
Tubulogenesis assay
The ability of L.s.-P and its fractions to modulate angiogenesis
in vitro was evaluated in a capillary tube formation (tubulogenesis)
assay as previously reported [2]. Briefly, chamber slides were
coated with growth factor-depleted Matrigel (BD Pharmingen) for
1 h at 37uC. HUVECs resuspended in M199 containing 10% FBS
were seeded on Matrigel (56104/well). L.s.-P or its fractions
(L.s.-1.0 and L.s.-1.25) were added at a final concentration of
100 mg/ml. After an incubation of 18 h at 37uC and 5% CO2,
cultures were photographed. For each individual well, three
digitalized pictures were taken from different fields. Pictures were
analyzed by ImagePro Plus software (Media Cybernetics, Silver
Spring, MD) and closed areas (tube-like structures) were counted.
The extension of tube formation was expressed as the percentage
of tubes identified on treated samples versus controls. The final
results were pooled from at least three separate experiments.
Plasminogen Activator Inhibitor-1 (PAI-1) antigen assay
Levels of PAI-1 antigen were measured in conditioned media
(CM) from HUVECs plated on Matrigel for the tubulogenesis
assay in the presence or absence of L.s.-P or its fractions. After
20 h of incubation, CM were collected, centrifuged and stored.
Five ml of CM were used for the measurement of PAI-1 using an
enzyme-linked immunosorbent assays (ELISAs) (American Diag-
nostica GmbH, Germany).
In vitro platelet-tumor cell adhesion assay
For the tumor cell adhesion assay, platelet-coated surfaces were
generated as described [2]. Briefly, 36107 platelets resuspended in
HEPES Tyrode’s buffer were added to flat-bottomed plastic
microtiter wells. The plate was incubated for 1 h at RT. Afterwards,
the same volume of a HEPES Tyrode’s buffer enriched with 2 mM
CaCl2 was added to platelets. Then, plates were left at 4uC
overnight, non-adherent platelets were removed by washing with
1% BSA solution in phosphate buffered saline (PBS), and the
adhered platelets were then incubated for 1 h at 37uCwith 200 ml of
1% BSA solution in PBS in order to block "free-adhesive" sites on
the plastic surface. Tumor cells were detached and re-suspended in
PBS enriched with CaCl2 and MgCl2. After counting, 1610
5 cells
were added to each platelet-coated well in the presence or absence
of 100 mg/ml of L.s.-P, L.s.-1.0 or L.s.-1.25, and incubated at
37uC for 1 h. The plates were then washed twice and fixed with
methanol. Adherent cells were stained by haematoxylin in order to
make nuclei visible. Different fields were photographed, and the
number of adherent cells was evaluated by counting.
In vivo angiogenesis and tumor growth
This work has been approved by the Institutional Ethics
Committee and Review Board of the Institute of Biology and
Table 1. Sulfate content, anti-inflammatory and anti-coagulant activities of the polysaccharide preparations from L. saccharina
brown seaweed.
Sample Inflammation b APTT, U/mg c Sulfate content
Dose mg/kg Number of PMNs per rat (6106) Inhibition (% to control)
Controla - 49.165.5 - - -
L.s.-P 1.0
4.0
7.662.7
3.260.6
84.5
93.4
36.461.7 28.8
L.s.-1.0 1.0
4.0
16.261.5
8.461.3
67.0
82.9
6.860.2 16.2
L.s.-1.25 1.0
4.0
5.861.9
2.260.6
88.2
95.5
29.261.6 36.8
aSix animals received 0.9% (wt/vol) NaCl instead of polysaccharides.
bThe anti-inflammatory activity was determined as the effect on PMN transmigration to the peritoneal cavity of rats (six animals in each group, for details see Results).
The polysaccharide preparations were injected intravenously with a dose of 1.0 and 4.0 mg/kg of the rat weight. Data are presented as mean 6 SEM. N is the number
of rats in the group.
cAnticoagulant activity was measured as the APTT related to a heparin standard with an activity of 140 U/mg. Data are shown as mean 6 SEM; N= 4.
doi:10.1371/journal.pone.0017283.t001
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Experimental Medicine (IBYME; Buenos-Aires, Argentina) of
National Council of Scientific and Technical Investigations
(CONICET) (approval #A5072-01 014/1) and conducted in
accordance with the ‘‘Principles of laboratory animal care’’ (NIH
Publication no. 85-23, revised 1985). C57BL/6 (B6) mice were
injected with 500 ml Matrigel containing 16105 B16-F10 cells and
PBS as control or 100 mg of L.s.-P, L.s.-1.0 or L.s.-1.25.
Matrigel plugs were removed after 7 days and the extent of new
blood vessels formation was evaluated by hemoglobin content.
CD34+ cells present in Matrigel plugs were evaluated by flow
cytometry using a PE-conjugated anti-CD34 monoclonal antibody
(eBiosciences) on a FACSAriaTM (BD Biosciences). For confocal
microscopy analysis, mice were anesthetized and cardiac-perfused
with PBS and 4% paraformaldehyde and tissues were embedded
in frozen Optimum cutting Temperature (OCT) medium. Tumors
were cut (30 mm) in a cryostat and were frozen at -70uC. For
immunohistochemical staining, section samples were dried at RT
and fixed in acetone for 10 min at 220uC. After air-drying for
5 min, the nonspecific binding sites were blocked by incubation for
1 h at RT in 10% normal rat serum. Sections were stained with
the rat anti-mouse PECAM-1/CD31 (clone MEC13.3; BD) at
1:200 dilution overnight at 4uC followed by goat anti-rat
AlexaFluor 596 conjugate (Cell Signaling), 1:1000 for 1 h at
RT. The slides were washed and mounted in Fluormount
mounting medium, and immunofluorescence images were col-
lected on a Nikon E800 confocal microscope. Microvessel density
(MVD) was determined by counting the number of microvessels in
five randomly selected fields (200X) per tumor.
For long-term in vivo experiments, L.s.-P or its fractions were
administered i.p. every 3 days, starting from 24 h after Matrigel
injection. The animals were examined daily, and the body weight
was recorded twice weekly. Details on doses and schedules of
treatments are given in the relevant figure legends. Matrigel plugs
were removed on the day 21 post-implantation, weighed,
photographed and processed. Parameters of angiogenesis were
evaluated as above.
Rat peritoneal inflammation model
This work has been approved by the Institutional Ethics
Committee and Review Board of the V.N. Orekhovich Research
Institute of Biomedical Chemistry, Russian Academy of Medical
Sciences (approval#7-2007 of June 11, 2007). A rat model of acute
peritonitis was used as described [2] with some modifications. Nine
ml peptone (8.0% solution in 0.9% NaCl) were injected i.p. into
female Wistar rats (about 250 g, six animals in each group) under
ether anesthesia. Solutions of tested L.s.-polysaccharides (with a
dose of 1.0 and 4.0 mg/kg of the rat weight) in sterile 0.9% NaCl
(0.3 ml) were injected into the femoral veins of the animals 15 min
after peptone injection. The same volume of 0.9% NaCl was
injected to control animals. After 3 h, animals were anesthetized
and sacrificed, and their peritoneal cavities were washed with 30 ml
of PBS containing 60 U/ml heparin, 0.02% ethylenediaminetetra-
acetic acid (EDTA), and 0.03% bovine serum. The cell number in
the lavage was determined, and the cell suspension was concen-
trated by centrifugation at 4006g for 10 min. After 1:1 dilution with
bovine serum, the smears were prepared and stained by the
Pappenheimmethod. The number of PMNs was determined in two
parallel smears, each containing 600 cells.
Statistical Analysis
Statistical significance was determined with the Student’s t test.
P values less than 0.05 were considered as significant. The Kaplan-
Meier and one-way ANOVA analysis was used to establish
statistical significance for in vivo experiments.
Results
Chemical structure of fucoidan fractions from brown
algae of L. saccharina
Among the polysaccharides of nine different brown algal
species, those derived from L. saccharina, L.s.-P, were found to
be the most potent in terms of anti-inflammatory, anti-coagulant,
anti-adhesive and anti-angiogenic activities [2,9]. To evaluate the
chemical determinants of L.s.-P responsible for the distinct
biological activities, we proceeded to its fractionation by using ion-
exchange chromatography [10]. Surprisingly, two major fractions
related to different types of O-sulfated polysaccharides were
obtained: mannoglucuronofucans (fraction L.s.-1.0) and sulfated
fucoidans (fraction L.s.-1.25), which consist mainly of fucose units
and have a higher degree of sulfation (Figure 1 and Table 1).
Figure 1 shows the essential structural motifs of the polysaccha-
rides from L.s.-1.0 and L.s.-1.25, whose monosaccharide units
have partial sulfations at the indicated sites [10]. To compare the
biological profiles of the parent non-fractionated polysaccharide
L.s.-P and its fractions L.s.-1.0 and L.s.-1.25, we examined
their biological properties in terms of anti-coagulant, anti-
inflammatory, anti-adhesive, anti-angiogenic and anti-tumor
activities using different bioassays [2].
Anticoagulant activities of fucoidan fractions from brown
algae of L. saccharina
While studying the activities of fucoidans from eleven brown
algae species, we have shown that the total fucoidan from L.
saccharina (L.s.-P) was the most active anticoagulant in the APTT
test [2,8]. Comparative studies of anticoagulant activities of L.s.-
P, fractions L.s-1.0 and L.s-1.25 demonstrated that the L.s.-
1.25 fraction exhibits higher activity than the L.s.-1.0, probably
due to structural differences in sulfate contents (Table 1). Notably,
the starting preparation L.s.-P was slightly more active than L.s.-
1.25 in spite of its lower sulfate content. This fact may be
explained by the synergistic action of both fractions L.s.-1.0 and
L.s.-1.25 present in combination or by the loss of more active
minor components of L.s.-P during the fractionation.
Anti-inflammatory activities of fucoidan fractions from
brown algae of L. saccharina
We have previously shown that fucoidans from L. saccharina
interfere with L- and P-selectins, thus promoting a decrease in
PMN transmigration to the abdominal cavity and blocking the
induction of acute peritonitis [16]. In the present study, by using
the same acute peritonitis rat model, we explored the effect of the
L. saccharina-derived fractions L.s.-1.0 and L.s.-1.25 on PMN
transmigration. Our results demonstrate that both the L.s.-1.0
and L.s.-1.25 fractions at a dose of 1 mg/kg inhibited, although
at different extents, PMN influx into the peritoneal cavity (Table
1). As compared to the control, L.s.-1.25 significantly inhibited
the PMN influx (89.3%, P,0.05) with an activity similar to that of
L.s.-P. However, although statistically significant (P,0.05), the
effect of L.s.-1.0 was less pronounced (68%).
Effects of fucoidan fractions from brown algae of L.
saccharina on PMN adhesion to platelets under flow
conditions
Blocking of P-selectins represents one of the mechanisms
underlying the efficacy of fucoidans in reducing PMNs transmi-
gration in vivo, as suggested by the studies on PMN adhesion to
platelet-coated surfaces under flow conditions [2]. In this assay,
blockage of either P-selectin or b2-integrin by using the specific
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antibodies WAPS (not shown) or IB4 prevented PMN adhesion
either completely or partially. To confirm the ability of fucoidan
fractions to block such an interaction, 100 mg/ml of each
polysaccharide was pre-incubated with platelets before PMN
infusion. As shown in Figure 2, addition of L.s.-1.25, as well as
L.s.-P, was able to reduce the number of adherent PMN down to
30%, whereas L.s.-1.0 was not effective in modulating this effect.
To gain further mechanistic insights, IB4-pretreated PMNs were
also assayed (Figure 2, opened bars). In this case, the inhibitory
activity of L.s.-1.25 was markedly augmented (almost 60% of
inhibition) when b2-integrin was blocked. These results suggest
that similar to the non-fractionated L.s.-P polysaccharides [2,15],
L.s.-1.25 fraction inhibits PMN adhesion to platelets through a P-
selectin-dependent mechanism.
Effects of fucoidan fractions from brown algae of L.
saccharina on FBS-induced HUVEC capillary-like
structures formation in vitro
As previously established, the non-fractionated fucoidan prep-
aration L.s.-P from L. saccharina has a pronounced anti-angiogenic
activity demonstrated by its ability to reduce FBS-induced
HUVEC tubulogenesis [2]. In the present study, we aimed to
identify the fractions retaining these properties. As shown in Figure
3, addition of 100 mg/ml L.s.-1.25 to HUVEC suspensions
before plating completely prevented (99% of inhibition; P,0.001)
tube formation, showing, a comparable inhibitory effect to that
induced by L.s.-P, whereas L.s.-1.0 displayed no significant
biological activity. Remarkably, endothelial cell morphogenesis
was still significantly inhibited when lower concentrations of L.s.-
1.25 were used (Figure 3B). As our previous results, [17] we
measured the levels of PAI-1 in HUVEC embedded in Matrigel
cultured in the presence or absence of fucoidan fractions. The
levels of PAI-1 were markedly reduced (almost 60% and 47%
respectively) when L.s.-P and L.s.-1.25 were added to HUVEC
cultures while L.s.-1.0, which was not capable of influencing
HUVEC tubulogenesis, did not affect PAI-1 release from these
cells (data not shown).
Effects of fucoidan fractions from brown algae of L.
saccharina on bFGF-mediated angiogenesis
bFGF is an essential mediator capable of regulating angiogenesis
[18]. We examined whether the parent fucoidan from L. saccharina
or its fractions could selectively modulate bFGF-mediated events.
We initially investigated the effect of such polysaccharides by
targeting bFGF-induced HUVEC tubulogenesis For such assay,
each polysaccharide and bFGF were added before plating HUVEC
onto Matrigel. As shown in Figure 4A–B, addition of 100 mg/ml
Figure 2. Effect of L.s.-P and its fractions L.s.-1.0 and L.s.-1.25
on PMN adhesion to platelet-coated surface under flow
conditions. Polysaccharide fractions L.s.-1.0 and L.s.-1.25 or a
parent mixture L.s.-P were added at a final concentration of 100 mg/ml
to a platelet-coated surface and incubated for 10 min at RT. The same
concentration of each compound was also added to non-treated (filled
bars) or IB4-pretreated (grey bars) PMN suspensions before addition to
platelets. Under the flow conditions, migration of PMN was monitored
and photographed. Analysis was performed by counting the number of
attached PMN per field in at least 4 different fields. The mean
percentage6 SEM with respect to control of at least three independent
experiments is represented. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0017283.g002
Figure 3. Selective inhibitory effects of L.s.-P and its fractions
L.s.-1.0 and L.s.-1.25 on FBS-induced HUVEC tubulogenesis. (A)
Representative photographs of HUVEC cultured on Matrigel in the
presence of FBS along with 100 mg/ml of indicated parent fucoidan or
purified fractions. (B) Quantitative analysis of tube-like structures in
vitro using three different polysaccharide concentrations. Analysis was
obtained by counting closed areas (tubes) in at least four different
fields. Data are collected from at least three independent experiments.
All data were expressed as the percentage of tubes/cm2 of treated cells
vs control: filled, open and grey bars indicate the effect induced by 100,
10 or 1 mg/ml polysaccharides respectively.
doi:10.1371/journal.pone.0017283.g003
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parent fucoidan from L. saccharina (L.s.-P) or the L.s.-1.25 fraction
blocked (99% inhibition, P,0.001) bFGF-induced HUVEC tube
formation, while L.s.-1.0 had no effect.
The particular chemical structure and conformation of
fucoidans suggested the possibility that these polysaccharides
may directly interfere with the binding of growth factors to their
specific cognate receptors [3,19]. Therefore, we examined the
ability of each fraction to interfere with bFGF-receptor interac-
tions on BALB/c 3T3 fibroblasts [20]. Parent sulfated polysac-
charides (L.s.-P) or the above-mentioned fractions were added
separately at final concentrations of 100 mg/ml to fibroblasts
suspensions on bFGF-coated plates. As shown in Figure 4C–D,
adhesion of fibroblasts to bFGF was completely abolished by L.s.
-P or L.s.-1.25 preparations, but not by L.s.-1.0.
Effects of fucoidan fractions from brown algae of L.
saccharina on in vivo tumor growth and angiogenesis
Given their ability to influence endothelial cell biology in vitro,
we further studied the effects of the total sulfated polysaccharide
preparation from L. saccharina (L.s.-P) and its purified fractions on
tumor growth and tumor-related angiogenesis in vivo. For this, B6
mice were injected s.c. with Matrigel plugs enriched with
Figure 4. (A-B) Specific effect of L.s.-P and its fractions L.s.-1.0 and L.s.-1.25 on the inhibition of bFGF-induced HUVEC
tubulogenesis. (A) Representative photographs of HUVEC cultured on Matrigel in the presence of bFGF along with 100 mg/ml of the indicated
polysaccharide preparations. (B) Quantitative analysis of tube-like structures. All data were expressed as the percentage of tubes/cm2 vs control
(bFGF). (C,D) Specific effect of L.s.-P and its fractions L.s.-1.0 and L.s.-1.25 on the inhibition of Balb/c 3T3 adhesion to bFGF. (C) Effects of L.s.-P and
L.s.-1.25 on fibroblast cell adhesion to bFGF. Representative images of fibroblast cell adhesion to purified bFGF are shown. The images are
representative of three independent experiments. Quantification was performed by counting adhered cells of at least three different fields. Results
are expressed as percentage of the treated sample with respect to control (D). ***P,0.001.
doi:10.1371/journal.pone.0017283.g004
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melanoma B16-F10 cells as described [21] and 100 mg of L.s.-P
or the same amount of each fraction. Six to seven days after
implantation, Matrigel plugs were collected to determine hemo-
globin content and the frequency of CD34+ endothelial cells,
which represent reliable measurements of neovascularization. As
compared to control Matrigel plugs, those containing L.s.-P or
L.s.-1.25, but not L.s.-1.0 fraction, showed a significant
reduction in the levels of hemoglobin content (Figure 5A) and
the frequency of CD34+ cells (Figure 5B), suggesting important
effects on angiogenesis. However, in vitro exposure to L.s.-P, L.s.-
1.0 or L.s.-1.25 did not affect melanoma cell proliferation (Figure
5C), ruling out a direct effect of these polysaccharides on tumor
cell growth.
Given their pronounced anti-angiogenic effects, we further
explored the effect of therapeutic i.p. injection of different
polysaccharides in mice bearing B16-F10 melanoma Matrigel-
plugs. To this end i.p. treatments (50 mg/kg) were performed twice
a week starting from the day following Matrigel sponge
implantation. A significant reduction of tumor angiogenesis and
microvessel density was observed only in mice receiving L.s.-P or
Figure 5. Effect of polysaccharide preparations on tumor growth and angiogenesis in vivo. C57BL/6 (B6) mice were injected with 500 ml of
Matrigel containing 16105 B16-F10 cells in PBS or 100 mg of a non-fractionated polysaccharide mixture L.s.-P or its fractions L.s.-1.0 and L.s.-1.25.
After 6–7 days, tumors were removed and hemoglobin content was evaluated by using the Drabkin colorimetric method. Results are expressed as the
amount of hemoglobin (mg)/Matrigel weight (mg) (A) (**P,0.01). (B) Flow cytometry analysis of the frequency of CD34+ endothelial cells on Matrigel
plugs embedded with B16 melanoma cells. (**P,0.01) (C) In vitro cell growth of B16 melanoma cells exposed to 100 mg/ml of L.s.-P or its fractions
L.s.-1.0 and L.s.-1.25. Data are the mean 6 SEM of three independent experiments. (D) B6 mice were injected with 500 ml Matrigel containing
16105 B16-F10 cells. L.s.-P or its fractions L.s.-1.0 and L.s.-1.25 were injected i.p. at doses of 50 mg/kg every 3 days and compared to control (PBS).
Tumors were removed on day 21 post-implantation, photographed (D) and analyzed for CD31+ associated blood vessels (E), microvessel density (F)
and weight (G). (*P,0.05; **P,0.01).
doi:10.1371/journal.pone.0017283.g005
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L.s.-1.25, but not in mice treated with L.s.-1.0 (Figure 5D–F).
These anti-angiogenic effects were accompanied by a significant
reduction in tumor weight in L.s.-P- or L.s.-1.25-treated mice
(Figure 5G). Importantly, the mean weight of animals treated with
L.s.-P or its fractions did not differ from that of control animals,
and no significant histopathologic changes were observed in
sections of liver, spleen and lung of treated versus untreated mice
(data not shown), suggesting that fucoidans or their purified
fractions have no substantial toxic effects at least at the
concentrations tested.
Effect of fucoidan fractions from brown algae of L.
saccharina on breast cancer cell adhesion to human
platelets
We have recently demonstrated that the pool of sulfated
polysaccharides from L. saccharina efficiently blocks the adhesion of
a highly metastatic tumor cell line to human platelets [2],
suggesting that this compound could also be a promising inhibitor
of one of the earliest processes favouring tumor metastasis [22].
Here we examined the ability of L.s.-1.0 and L.s.-1.25 fractions
to abrogate breast cancer cell adhesion to platelet-coated surfaces.
Each preparation was added at a final concentration of 100 mg/ml
to MDA-MB-231 breast cancer cell suspension before plating the
cells, which were left to adhere to platelet-coated surfaces for 1 h.
As shown in Figure 6A–B, the non-fractionated preparation L.s.
-P inhibited tumor cell adhesion to platelets by 80%. Interestingly,
both isolated fractions L.s.-1.0 and L.s.-1.25 significantly
suppressed these heterotypic interactions, but L.s.-1.25 fraction
was much more active than L.s.-1.0 (80%; P,0.003 reduction vs
30% reduction; P,0.05). These results demonstrate that the
ability of L.s.-P to inhibit heterotypic cell adhesion between
tumors and human platelets is mainly associates with the effect of
the L.s.-1.25 fraction.
Discussion
Data from over 700 studies indicate that fucoidans from brown
seaweeds are endowed with great potential as safe nutritional and
possible therapeutic agents for a wide variety of health complaints.
These sulfated biopolymers are represented by very complex and
structurally heterogeneous polysaccharides, which mainly contain
substantial percentages of L-fucose and sulfate ester groups
together with other types of monosaccharides, uronic acid, acetyl
groups, and other non-carbohydrate substituents [3,6]. Although
such properties make very difficult the detailed structural
elucidation of fucoidans, increasing efforts are devoted to the
identification of a novel structure-activity relationship. It has been
shown that the chemical structures of fucoidans vary from species
to species and different extraction and/or purification methods
could substantially change the bioactivity of fucoidans by
modifying the parent chemical structures [3,10,15]. These data
have reinforced the notion that several chemical features of
fucoidans can profoundly influence their bioactivities. In accor-
dance, we have recently reported that, among fucoidans derived
from nine different brown algal species, the polysaccharide isolated
from L. saccharina (renamed as Saccharina latissima) represents the
most powerful inhibitor endowed with anti-inflammatory, anti-
coagulant, anti-adhesive, and anti-angiogenic properties [2].
The aim of the present study was to delineate chemical motifs of
the fucoidan structure of L. saccharina, which might reflect
improved biological activities of these polysaccharides, mainly
those related to cancer biology. Using ion-exchange chromatog-
raphy the parent polysaccharide L.s.-P was separated into two
main fractions related to two different types of sulfated
polysaccharides: fucomannoglucuronan (fraction L.s.-1.0) and
fucan (fraction L.s.-1.25) [10]. The latter fraction consists mainly
of fucose units and has a higher degree of sulfation (Figure 1). To
compare the biological activities of the parent polysaccharide
L.s.-P with those of its derived fractions L.s.-1.0 and L.s.-1.25,
we evaluated their anti-coagulant, anti-inflammatory, anti-adhe-
sive, anti-angiogenic, and anti-tumor effects.
Fucoidans, like heparin, represent promising anti-coagulant
agents, being able to affect different coagulation pathways [23,24].
As a result, in the past years, fucoidans have been recommended
as substitutes for heparin in the therapy of thrombosis [23], thus
avoiding the risk of ‘‘prion’’ contamination affecting mammalian-
derived compounds. Due to the clinical relevance of these
therapies, several attempts have been made to enhance the anti-
coagulant activity of fucoidans. In this respect, it has been
suggested that the enhanced activity correlates with some chemical
characteristics, such as the sugar composition (fucose, galactose,
etc.), the sulfate content and position and the molecular weight [3].
A similar relationship was confirmed by studies on sulfated fucans
isolated from marine invertebrates (the jelly coat of sea urchin eggs
Figure 6. Selective effects of L.s.-P and its fractions L.s.-1.0 and
L.s.-1.25 on breast cancer cell adhesion to human platelets. (A)
MDA-MB-231 breast cancer cells were pre-incubated with selected
polysaccharide preparations prior to exposure to human platelet-
coated plates. The images are representative of three independent
experiments. (B) Quantitative analysis of cell adhesion was performed
by counting the number of tumor cells adhered to at least three
different fields. Results are expressed as mean percentage 6 SEM of the
treated samples versus control. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0017283.g006
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and the body wall of sea cucumbers), which possess, unlike brown
algal fucoidans, a regular structure [25]. In addition to a series of
relevant features, we found that the presence of the 2-O-a-D-
glucuronyl branch may decrease the anti-coagulant properties of
fucoidans, as in the case of a fucoidan from the brown algae C.
okamuranus [2]. Interestingly, in this study only one of the isolated
fractions, namely, L.s.-1.25, could successfully prolong the APTT
time in the human plasma coagulation test, as shown in Table 1.
This effect could be associated to the higher sulfate content present
in L.s.-1.25.
Another interesting feature of fucoidans is represented by their
anti-angiogenic and anti-tumoral activities. Inhibiting or normal-
izing the formation of tumor vascular networks represents a
promising strategy for controlling several malignancies [26]. More
than 75 inhibitors of angiogenesis have been included in clinical
trials, but only few of them were found to be efficient as single-
therapy for advanced tumors [27]. This lack of success could be
explained by the presence of alternative mechanisms that may
compensate for the blockade of canonical angiogenic pathways,
mainly those triggered by the vascular endothelial growth factor
(VEGF) and the bFGF. Moreover, it has been proposed that some
anti-angiogenic agents may augment tumor hypoxia by inducing
endothelial cell apoptosis, thus facilitating tumor progression and
metastasis [27]. These clinical observations prompted the
identification of novel anti-angiogenic agents capable of promoting
vascular remodeling without drastically altering endothelial cell
survival. In this respect, fucoidans from L. saccharina represent
promising candidates for novel anti-tumor therapies, as it is a non-
toxic naturally occurring compound, which can be potentially
produced in a large scale and could influence different angiogenic
and metastatic-related processes [2]. Moreover, as mentioned
above, it is highly feasible to improve fucoidan biological activity
by the separation of more active fractions and even chemical
manipulation. For instance, it has been shown that an additional
sulfation can increase the anti-angiogenic and anti-tumoral
activities of the fucoidan from F. vesiculosus [28].
Here we demonstrate that only one fraction (L.s.-1.25) derived
from parent polysaccharide L.s.-P, which is composed of O-
sulfated fucose units, represents an inhibitor of in vitro HUVEC
angiogenesis, as shown by reduction of FBS-induced tubulogenesis
(Figure 3) and PAI-1 levels (data not shown) Although the
mechanisms underlying the inhibition of in vitro tubulogenesis are
not fully understood, interference of fucoidans with the activities of
the relevant angiogenic growth factors has been proposed [3,28,29].
In this regard, a recent study has documented the ability of
fucoidans to inhibit VEGF-induced angiogenesis and tumor
neovascularization in vivo, likely through modulation of cell surface
neuropilins (NRP1 or NRP2) and other VEGF receptors [19]. In
addition, other studies reported that both the sulfation and size of
polysaccharides are critical for NRP1 internalization [30]. Illustrat-
ing this concept, a low-molecular-weight (5,000 Da) fucoidan did
not reduce the cell surface NRP1 levels in endothelial cells. These
results are consistent with the critical role of glycosylation in the
regulation of inflammation and angiogenesis [31,32].
Supporting these findings, here we demonstrated that a mixture
of sulfated polysaccharides from L. saccharina (L.s.-P) or its fraction
L.s.-1.25 can inhibit bFGF-induced tubulogenesis (Figure 4A–B)
by interfering with the binding of this growth factor to its cell surface
receptors and heparin sulfate proteoglycans [20]. Moreover,
preliminary data confirmed the ability of both L.s.-P and L.s.
-1.25 to neutralize the effect of other important mitogenic factors,
such as the platelet-derived growth factor (PDGF), as suggested by
tubulogenesis experiments of PDGF-induced transfected PAECs
(not shown). Collectively, these data indicated that fucoidan fraction
L.s.-1.25 obtained from L. saccharina could serve as a specific
inhibitor of angiogenesis in vitro. This concept is strengthened by the
finding that fucoidan fractions act as a potent P-selectin inhibitor
[2]. P-selectin, a critical cell adhesion molecule expressed either by
platelets or activated endothelium, is directly involved in the
development of inflammatory processes [8], but can also contribute
to angiogenesis by promoting endothelial cell migration [33].
Moreover, P-selectin also plays a key role in the initial process of
tumor cell adhesion to vascular endothelial cells and in heterotypic
interactions between activated platelets and tumor cells during
metastasis [22]. Therefore, P-selectin blockade is not only envisaged
as a promising anti-inflammatory strategy but also represents a
potential approach to suppress angiogenesis and metastasis by
inhibiting endothelial cell migration and disrupting the formation of
tumor cell-platelet emboli complexes. Interestingly, we found that
the L.s.-1.25 fraction markedly inhibits adhesion of theMDA-MB-
231 breast cancer cell to human platelets. As previously described,
the contribution of other adhesion molecules is assured in such a
phenomenon, since the single use of anti-P selectin WAPS
monoclonal antibody was not sufficient to impair cell-cell adhesion
[2]. Hence, the fucoidan fraction L.s.-1.25 might potentially
neutralize other important players involved in tumor cell adhesion
including thrombospondin or integrins [2].
The effectiveness of sulfated polysaccharides from L. saccharina on
angiogenesis was also evaluated in vivo. Our results show that non-
fractionated polysaccharides L.s.-P and the fucoidan fraction L.s.-
1.25, but not the mannoglucuronofucan fraction L.s.-1.0,markedly
reduce tumor-associated angiogenesis and growth of melanoma cells
in vivo. This finding was not related to an effect of polysaccharide
samples on the intrinsic proliferative properties of melanoma cells,
since they had a similar growth rate as shown by the MTT assay
following treatment with either control PBS, L.s.-P, or its fractions
L.s.-1.25 or L.s.-1.0. Moreover, we found a significant reduction of
tumor-associated blood vessels and tumor growth when L.s.-P or
L.s.-1.25 was administered in vivo in tumor-bearing mice.
Importantly, we could find no signs of toxicity associated to changes
in body weight or alterations in the histology of different organs as
previously demonstrated in other settings [34–36]. In this regard,
several studies showed that prolonged administration of fucoidans is
not toxic with regards to body weight variations, haematological
disorders or histopathologic alterations [34–36].
In spite of the fact that brown seaweed fucoidans have been the
subject of many different biomedical investigations, their structures
need to be characterized in more detail. In previous report [2,9],
we could not detect minor sulfated fucoglucuronan, fucoglucur-
onomannan, and fucogalactan in fucoidans from L. saccharina.
These components were not easily detectable in total fucoidan
extracts and became visible only after the fractionation by ion-
exchange chromatography, as described here. Thus, the use of
commercially available crude fucoidan samples in the investigation
of structure-activity relationships is not recommended due to
structural uncertainty of such polysaccharide preparations.
To the best of our knowledge, this is the first report describing the
L. saccharina fucoidan as a powerful in vivo inhibitor of tumor-related
angiogenesis and tumor growth, as well as heterotypic cell adhesion.
These activities appear to correlate with the presence of high levels
of O-sulfated fucose units in the fraction L.s.-1.25. Lower activity
of the fraction L.s.-1.0 in a number of assays performed could be
linked to the presence of mannose and glucuronic acid units in its
structure. In light of our findings, the L. saccharina fucoidan fraction
L.s.-1.25 may be amenable to be tested in pilot clinical trials.
In order to decipher the structure of the corresponding
pharmacophores, a systematic synthesis of the oligosaccharide
fragments of different fucoidans [37–39] will be required including
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that of per-O-sulfated oligosaccharides [40,41]. Assessment of the
structure-function relationship of different purified fucoidan
fractions may contribute to an improved understanding of the
mechanisms underlying the anti-inflammatory, anti-tumor and
anti-angiogenic activities of sulfated polysaccharides in vivo in order
to accelerate their use in clinical settings.
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